BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II.
BN 80927, a novel homocamptothecin derivative, inhibits both topoisomerase I and topoisomerase II mediated DNA relaxation and shows pronounced cytotoxicity against HT29, SKOV-3, DU145 and MCF7 human tumor cell lines.
Lavergne
O
O
Institut Henri Beaufour, Les Ulis, France.
Harnett
J
J
Rolland
A
A
Lanco
C
C
Lesueur-Ginot
L
L
Demarquay
D
D
Huchet
M
M
Coulomb
H
H
Bigg
D C
DC
D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology; D004354:Drug Screening Assays, Antitumor; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; C121907:BN 80927; D004791:Enzyme Inhibitors; D059004:Topoisomerase I Inhibitors; D059005:Topoisomerase II Inhibitors; D002166:Camptothecin